Agentix Corp. reported its financial results for the three months ending June 30, 2025, revealing a net loss of $185,824, compared to a loss of $150,717 during the same period in 2024. The company's total operating expenses increased to $200,342 from $151,305 year-over-year, primarily driven by higher research and development costs, which rose to $100,000 from $55,501. The increase in expenses reflects the company's ongoing commitment to developing therapeutic agents for metabolic diseases, including Type 2 diabetes and obesity.
In terms of financial position, Agentix Corp. reported total current assets of $4,412 as of June 30, 2025, a significant decrease from $100,274 at the end of the previous fiscal period. The company's total liabilities increased slightly to $3,276,178 from $3,204,523, with accounts payable to related parties rising to $2,148,663 from $1,932,438. The accumulated deficit also widened to $6,707,352 from $6,521,528, indicating ongoing challenges in achieving profitability.
The company has not reported any significant acquisitions or product launches during this quarter. However, it continues to focus on its core operations and research initiatives. The headcount remains stable at 40,066,951 shares outstanding, with no changes in the number of shares issued. The company’s cash position at the end of the reporting period was $4,412, raising concerns about its ability to sustain operations without additional funding.
Agentix Corp. has indicated that it is actively seeking to generate sufficient revenue and secure additional financing to support its operations. The company’s management has expressed optimism about its market opportunities but acknowledges the challenges posed by current economic conditions and the need for further investment. The outlook remains cautious, with the company emphasizing the importance of executing its business plan to improve its financial standing and operational viability.
Overall, Agentix Corp. is navigating a challenging financial landscape, with increased losses and a declining cash position. The company is focused on its research and development efforts while seeking to stabilize its financial health through potential funding and revenue generation strategies.
About Agentix Corp.
Agentix Corp. is a clinical-stage biotechnology company focused on developing novel therapeutics for metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic fatty liver disease. Its pipeline features peripherally-restricted cannabinoid receptor 1 antagonists designed to avoid central nervous system side effects. Agentix aims to advance early clinical development and partner with larger biopharma firms for commercialization, targeting a global market affected by metabolic syndrome.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.